Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Summary

The primary purpose of this study was to demonstrate a biological effect of AL-78898A, as measured by change (reduction) in central subfield (CSF) retinal thickness 4 weeks after a single intravitreal injection, as compared to LUCENTIS.

Timeline

Start

2011-06

Primary completion

2012-04

Completion

2012-04

Drugs

Indications